Table 5.
RR for exacerbations during follow-up according to different severity scores
| Cohort | Scores | RR—mild | RR—moderate | RR severe |
|---|---|---|---|---|
| Dundee, Scotland (n=494) |
BSI | 0.66 (0.53 to 0.82)* | 1.00 (reference) | 2.14 (1.84 to 2.50)* |
| FACED | 0.91 (0.77 to 1.06) | 1.00 (reference) | 1.44 (1.15 to 1.80)* | |
| Galway, Ireland (n=280) |
BSI | 0.70 (0.55 to 0.88) | 1.00 (reference) | 1.44 (1.16 to 1.78)* |
| FACED | 0.74 (0.59 to 0.92)* | 1.00 (reference) | 1.25 (0.82 to 1.92) | |
| Monza, Italy (n=250) |
BSI | 0.76 (0.59 to 0.99)* | 1.00 (reference) | 1.38 (1.11 to 1.70)* |
| FACED | 1.06 (0.86 to 1.31) | 1.00 (reference) | 1.64 (1.24 to 2.17)* | |
| Leuven, Belgium (n=190) |
BSI | 0.78 (0.52 to 1.18) | 1.00 (reference) | 2.08 (1.52 to 2.84)* |
| FACED | 0.86 (0.64 to 1.14) | 1.00 (reference) | 1.51 (1.05 to 2.16)* | |
| Athens, Greece (n=159) |
BSI | 0.67 (0.34 to 1.33) | 1.00 (reference) | 1.92 (1.21 to 3.04)* |
| FACED | 1.20 (0.73 to 1.96) | 1.00 (reference) | 2.36 (1.33 to 4.21)* | |
| Newcastle, England (n=126) |
BSI | 0.47 (0.32 to 0.71)* | 1.00 (reference) | 1.29 (1.02 to 1.65)* |
| FACED | 0.81 (0.63 to 1.04) | 1.00 (reference) | 0.95 (0.64 to 1.41) | |
| Vojvodina, Serbia (n=113) |
BSI | 0.14 (0.05 to 0.38)* | 1.00 (reference) | 2.61 (1.69 to 4.04)* |
| FACED | 0.22 (0.13 to 0.37)* | 1.00 (reference) | 0.93 (0.49 to 1.77) | |
| Pooled cohort (n=1612) | BSI | 0.63 (0.52 to 0.78)* | 1.00 (reference) | 1.73 (1.42 to 2.12)* |
| FACED | 0.78 (0.60 to 1.01) | 1.00 (reference) | 1.40 (1.16 to 1.68)* |
*Indicates statistical significance at p<0.05. Pooled data were obtained through random effects meta-analysis.
BSI, Bronchiectasis Severity Index; RR, rate ratio.